Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China

Summary

The randomized phase 3 HERON-Lung01 trial evaluated the efficacy and safety of ruzaltatug rezetecan, a novel HER3-directed antibody-drug conjugate (ADC), compared with platinum-pemetrexed chemotherapy in 498 patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who progressed on prior EGFR tyrosine kinase inhibitor (TKI) therapy. At the prespecified interim analysis, ruzaltatug rezetecan significantly prolonged progression-free survival compared to chemotherapy (median 8.3 months vs 5.4 months; HR 0.47; p < 0.0001). The safety profile was manageable, with grade 3 or higher treatment-related adverse events occurring in 41% vs 39% of patients, predominantly hematological, and leading to treatment discontinuation in only 1% per arm. These findings establish ruzaltatug rezetecan as a promising post-TKI therapeutic option in advanced EGFR-mutated NSCLC.

Critical appraisal

Evidence level: Randomized, open-label phase 3 clinical trial (HERON-Lung01, n=498) providing high-level evidence for a HER3-directed ADC in the post-TKI setting. Effect size: Clinically and statistically significant improvement in progression-free survival (median 8.3 vs 5.4 months; HR 0.47 [95% CI 0.36–0.60], p < 0.0001). Biomarker context and translational impact: Targeted at activating EGFR mutations (ex19del, L858R) post-EGFR TKI failure, utilizing HER3 surface expression for payload delivery regardless of specific secondary resistance mechanisms. Practice implications: Findings support a potential shift in the standard-of-care paradigm post-TKI, providing an effective alternative to conventional platinum-pemetrexed chemotherapy. Time to clinical impact: 1–3 years, depending on regulatory filings and approvals in China and globally.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology